Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Immunotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Targeted Delivery of siRNA Therapeutics Using Ligand Mediated Biodegradable Polymeric Nanocarriers.
CONCLUSION: In this review, we provide ⅰ) an overview of the non-viral carrier associated with siRNA delivery for cancer treatment, and ⅱ) a description of the five major cancer-targeting ligands. PMID: 29962332 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - July 1, 2018 Category: Drugs & Pharmacology Authors: Jin HS, Soo CK, Hye AM, Sukdeb P, Pill-Hoon C, Sangshetti J, Arote RB Tags: Curr Pharm Des Source Type: research

Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research

Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy
In conclusion, these ROS-responsive NPs provided a promising strategy to combine siRNA-PD-L1 immunotherapy and Dox chemotherapy.Graphical abstract
Source: International Journal of Pharmaceutics - June 20, 2019 Category: Drugs & Pharmacology Source Type: research

Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle
ConclusionOverall, results revealed that the tumors treated with siPDIN restored the immunity of CTLs by potentially inhibiting the immune checkpoint interactions, suppressed the mTOR signaling pathway and exhibited an enhanced anticancer efficacy in melanoma.
Source: Pharmaceutical Research - May 30, 2020 Category: Drugs & Pharmacology Source Type: research

Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
ConclusionsThese findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.
Source: Pharmaceutical Research - February 15, 2022 Category: Drugs & Pharmacology Source Type: research

Sialic Acid-Targeted Cyclodextrin-Based Nanoparticles Deliver CSF-1R siRNA and Reprogram Tumour-Associated Macrophages for Immunotherapy of Prostate Cancer
Eur J Pharm Sci. 2023 Mar 20:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimulating...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research

Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer
Eur J Pharm Sci. 2023 Mar 21;185:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimula...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research

Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
Discussion: To our best knowledge, our study pioneered co-delivery system for hydrophilic siCD47 and hydrophobic R848. It can maximize break tumor immune escape caused by CD47 and simultaneously enhance antigen presentation by activating DCs for effector T cell killing while regulating the tumor microenvironment as expected. Not only does it conform to the reports of previous basic research, but also it can break the bottleneck of their clinical application hopefully. Collectively, our findings could lay the foundation for future therapeutic strategies of TNBC.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
In this study, we develop PDDS{polyethylene glycol-b-asparaginate(diethylenetriamine-vorinostat), (PEG-b-P[Asp(DET-SAHA)n] PPDS)}encapsulating siRNA-PD-L1to provide micelles siRNA-PD-L1-loaded micelles (siRNA@PPDS). Transmission electron microscope (TEM) images demonstrate that siRNA@PPDS micelles presented spherical morphology with a size of about 120 nm; hydrodynamic data analysis indicates pH sensitivity of siRNA@PPDS micelles. The experiments reveal that siRNA@PPDS micelles could be well uptaken by the tumor cells to silence the expression of PD-L1 protein in a dose-dependent manner; compared with the free SAHA, the SA...
Source: Drug Delivery - May 26, 2021 Category: Drugs & Pharmacology Authors: Fengkun Lu Lei Hou Sizhen Wang Yingjie Yu Yunchang Zhang Linhong Sun Chen Wang Zhiqiang Ma Feng Yang Source Type: research

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
ConclusionThese findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.
Source: Pharmaceutical Research - June 17, 2022 Category: Drugs & Pharmacology Source Type: research